Akari Therapeutics, Plc
AKTX
$3.06
-$2.09-40.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -40.46% | -121.07% | 74.93% | 33.44% | 8.84% |
| Total Depreciation and Amortization | -- | -- | -- | -- | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,050.96% | 8,127.12% | -254.41% | 1,210.11% | 122.37% |
| Change in Net Operating Assets | -98.70% | -142.72% | -120.27% | -64.52% | 699.48% |
| Cash from Operations | -43.17% | -42.35% | 33.47% | 46.83% | 51.83% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | 100.00% |
| Total Debt Repaid | 87.46% | 39.88% | 35.35% | -139.07% | -- |
| Issuance of Common Stock | 54.97% | -- | -53.98% | 53.09% | -11.11% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 167.41% | 528.22% | -56.45% | 40.89% | -38.75% |
| Foreign Exchange rate Adjustments | -100.00% | -250.00% | 300.00% | -- | -83.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 558.35% | 88.24% | -95.50% | 99.33% | 146.61% |